Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414839 | 0.88 | REN (0.42) | RENTACR1KCNH2USP30 | |
| SCHEMBL1229339 | 0.87 | REN (0.46) | RENKCNH2 | |
| SCHEMBL3108333 | 0.86 | REN (0.48) | RENKCNH2 | |
| SCHEMBL3111265 | 0.81 | REN (0.52) | RENJAK2JAK1KCNH2 | |
| SCHEMBL4155087 | 0.77 | JAK2 (0.40) | RENGPR119JAK2JAK1KCNH2 | |
| SCHEMBL3096976 | 0.77 | REN (0.45) | RENKCNH2 | |
| SCHEMBL1071703 | 0.76 | REN (0.48) | RENKCNH2 | |
| SCHEMBL3417760 | 0.75 | REN (0.51) | RENKCNH2 | |
| SCHEMBL12243834 | 0.73 | DDB1 (0.46) | GPR119JAK2JAK1DDB1CRBN | |
| SCHEMBL13538347 | 0.72 | REN (0.46) | RENKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249163-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-09-30 | — | — | US | disclosed |
| US-20100249163-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-09-30 | — | — | US | disclosed |
| US-20100249163-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-09-30 | — | — | US | disclosed |
| WO-2009070869-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249163-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885GPR119 435/4885JAK2 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.